יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Kamada Pharma (KMDA)
The share price retrospective for Kamada Ltd. (KMDA) on the GURU.Markets platform demonstrates an EV/EBITDA of 8.92. Kamada Ltd. (KMDA) operates advanced plasma fractionation facilities with continuous updates to its purification systems. Stringent FDA requirements and a robust patent portfolio protect the business from new entrants. However, the risk of synthetic analogs and competition with global industry leaders create significant challenges for growth.
פילוחי מדדים מקיפים ואנליטיקה עבור kamada.com (KMDA)
The EV/EBITDA multiple determines business value by combining market capitalization and net debt relative to operating profit. This calculation allows for the neutralization of tax burdens and debt structures when comparing assets. By analyzing business valuation through EV/EBITDA trends, an investor can identify the market premium relative to the company's value. For Kamada Ltd. (KMDA), this indicator is critical as it reflects the capitalization efficiency of profits derived from the sale of Glassia protein and specialized vaccines.
